Heilongjiang Feihe Dairy Co. Ltd.
11
1
1
5
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 45/100
0.0%
0 terminated/withdrawn out of 11 trials
100.0%
+13.5% vs industry average
9%
1 trials in Phase 3/4
20%
1 of 5 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (11)
Safety and Efficacy Evaluation of an Extensively Hydrolyzed Formula in Infants With Cow's Milk Protein Allergy (CMPA)
Role: lead
Improved Cognitive Outcomes Associated With Feihe HMO With DHA/ARA in Infant Formula
Role: lead
Improved Immunology Outcomes Associated With Lactoferrin Fortified With HMO in Infant Formula
Role: lead
Improved Gut Health Outcomes Associated With Probiotics Fortified With Hydrolyzed Whey Protein in Infant Formula
Role: lead
Effect of Oligosaccharides and Optimizing Multiple Nutrients to Infant Formula on Growth and Development of Infants
Role: lead
Odour Characteristics of Human Breast Milk of Chinese Mothers
Role: lead
The Effect of a New Infant Formula on Growth and Cognition in Healthy Term Infants
Role: lead
Safety and Nutritional Adequacy of a New Infant Formula in Healthy Term Infants
Role: lead
Molecular Structure and Content of Human Milk Oligosaccharides (HMOs) and Its Effect on Infant Health in China
Role: lead
Establishment of the Breast Milk Database in China
Role: lead
New Stage 1 Formula on Gut Comfort and Gut Health
Role: lead
All 11 trials loaded